Dr. Brentjens Discusses Targets for CAR T-Cell Therapy

Renier Brentjens, MD, PhD
Published: Thursday, Jan 04, 2018



Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.

CD19 is a well-established target in B-cell cancer, with 2 commercially available CAR T-cell therapies targeting tumor cells that express CD19.

Brentjens says that CD19 is only the beginning, as other targets are emerging such as BCMA. Clinical trials targeting BCMA in patients with relapsed or refractory multiple myeloma are currently ongoing.
 


Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.

CD19 is a well-established target in B-cell cancer, with 2 commercially available CAR T-cell therapies targeting tumor cells that express CD19.

Brentjens says that CD19 is only the beginning, as other targets are emerging such as BCMA. Clinical trials targeting BCMA in patients with relapsed or refractory multiple myeloma are currently ongoing.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x